Veru Inc (VERU NASDAQ) stock market data APIs
$0.6036
-0.01(-1.7%)
as of July 3, 2025
Try our APIs with
free plan!
Veru Inc Financial Data Overview
Price chart is built with
Anychart
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Prev. Close
0.6036
Open
0.5954
High
0.6224
Low
0.5852
52 wk Range
0.45-1.42
Market Cap
85 546 K
Shares Outstanding
147 M
Revenue
16 886 K
EPS
-0.0603
Beta
-0.786
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Veru Inc data using free add-ons & libraries
Get Veru Inc Fundamental Data
Veru Inc Fundamental data includes:
- Net Revenue: 16 886 K
- EBITDA: -40 755 344
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Veru Inc News
New
InvestingPro's Fair Value model captures 67% upside in Veru shares
When InvestingPro’s Fair Value models identified (NASDAQ:VERU) as significantly undervalued in January 2024, the healthcare company’s stock was trading at just $0.41. Today, that analysis has prov...
Veru And Two Other Penny Stocks To Consider
Over the last 7 days, the United States market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. For investors seeking opportunities beyond wel...
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; ...
Veru to Participate in the Virtual BTIG Obesity Health Forum
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
